EUVIMEDEUVIMED entdecken
Crossref

N ‐acetyl‐ D ‐mannosamine, a novel additive, effectively reducing high mannose glycosylation of monoclonal antibody without affecting other quality attributes

Miaomiao Chai, Hai Shu, Qiancheng Wang, Cong Tian, Linlin Wang, Yinmao Fan, Ruiqiang Sun iD, Hang Zhou

Biotechnology Progress · 2025

DOI: 10.1002/btpr.70024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biotechnology Progress, 2025. Verfasst von Miaomiao Chai und 7 weiteren Autor:innen. Beteiligte Einrichtung: Cell Culture Process Development (CCPD), WuXi Biologics INC., Shanghai, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Mannose, Hexosamines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

N‐linked glycosylation stands as a pivotal quality attribute for monoclonal antibodies (mAbs), particularly the high mannose (Man5) variant, which significantly influences the pharmacokinetics of mAbs. Traditional approaches to modulate Man5 have frequently resulted in suboptimal outcomes. In this investigation, we introduced a novel additive, N ‐acetyl‐ d ‐mannosamine (ManNAc), which selectively targeted and reduced Man5 without compromising other product quality attributes (PQAs). The study further examined optimal concentrations and timing for the incorporation of ManNAc in the mAbs expression process utilizing CHO‐K1 cells within a fed‐batch shaker flask culture mode. In the ManNAc titration experiments, we established groups at concentrations of 5, 10, 15, 20, 40, 60, 80, and 100 mM. The findings revealed a concentration‐dependent decrease in Man5, with reductions reaching as low as 2.9% from an initial 8.9%. Importantly, cellular growth, metabolism, and other PQAs remained unaffected. Regarding the timing of ManNAc addition, groups were set for days N‐1, 0, 5, and 11. The results indicated that ManNAc addition on Day 11 did not affect Man5 levels, whereas earlier additions proved effective. A full factorial design was employed to assess the interplay between ManNAc concentration and addition timing, revealing no significant interaction. Consequently, it is recommended to administer 20–40 mM ManNAc prior to Day 4. The strategy of introducing 20 mM ManNAc on Day 0 has been successfully implemented across 12 clones, achieving an average Man5 reduction of 46%. Collectively, these findings delineate a novel and efficacious strategy for the Man5 modulation, promising enhanced control over this critical quality attribute in mAbs production.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalMannoseHexosaminesCHO CellsCricetulusGlycosylationAnimalsCricetinae

Stichwörter der Autor:innen

ManNAc addition time introductionManNAc concentrationN‐linked glycosylationhigh mannosemonoclonal antibody

Substanzen

Antibodies, MonoclonalMannoseHexosaminesN-acetylmannosamine

Autor:innen und Institutionen

  • Cell Culture Process Development (CCPD), WuXi Biologics INC., Shanghai, China.
  • Bioprocess Research and Development (BRD), WuXi Biologics Inc., Shanghai, China.

ORCID-Profile: Ruiqiang Sun

Zitieren

APA

Chai, M., Shu, H., Wang, Q., Tian, C., Wang, L., Fan, Y., Sun, R., & Zhou, H. (2025). N ‐acetyl‐ D ‐mannosamine, a novel additive, effectively reducing high mannose glycosylation of monoclonal antibody without affecting other quality attributes. Biotechnology Progress. https://doi.org/10.1002/btpr.70024

Vancouver

Chai M, Shu H, Wang Q, Tian C, Wang L, Fan Y, et al. N ‐acetyl‐ D ‐mannosamine, a novel additive, effectively reducing high mannose glycosylation of monoclonal antibody without affecting other quality attributes. Biotechnology Progress. 2025. doi:10.1002/btpr.70024

BibTeX
@article{Chai2025,
  author = {Chai, Miaomiao and Shu, Hai and Wang, Qiancheng and Tian, Cong and Wang, Linlin and Fan, Yinmao and Sun, Ruiqiang and Zhou, Hang},
  title = {N ‐acetyl‐ D ‐mannosamine, a novel additive, effectively reducing high mannose glycosylation of monoclonal antibody without affecting other quality attributes},
  journal = {Biotechnology Progress},
  year = {2025},
  doi = {10.1002/btpr.70024}
}
Kostenlos starten →